ArticlePloS one2026
Comprehensive multi-omics analysis reveals prognostic, immune, and therapeutic signatures of TNFAIP family genes in breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor necrosis factor-alpha-induced proteins (TNFAIPs) are key regulators of inflammation, apoptosis, and immune signaling, yet their integrated roles in breast cancer (BC) remain poorly characterized. While individual TNFAIP members have been studied in other cancers, a comprehensive multi-omics characterization of this gene family in BC is still needed.
methodsWe performed an integrative bioinformatics analysis using public datasets (UALCAN, TIMER, bc-GenExMiner, cBioPortal, STRING, GeneMANIA, Enrichr, MethSurv, GDSC, CTRP, and HPA) to evaluate TNFAIP family members in BC. Expression, genomic alterations, methylation patterns, immune infiltration, and drug sensitivity were analyzed across clinical and molecular subtypes. Where applicable, multiple hypothesis testing was controlled using the Benjamini-Hochberg false discovery rate (FDR) method.
resultsAmong TNFAIPs, TNFAIP6 and EFNA1 were significantly upregulated in BC, while TNFAIP1, TNFAIP2, TNFAIP3, PTX3, TNFAIP8, and STEAP4 were downregulated. Elevated TNFAIP2, TNFAIP3, and TNFAIP8 expression correlated with improved overall survival (OS). Multi-database integration revealed that TNFAIP3 expression was strongly correlated with infiltration of CD4 ⁺ T cells, dendritic cells, and neutrophils. Functional enrichment highlighted the NF-κB, PI3K-Akt, and TNF signaling pathways as key regulatory axes. Drug-sensitivity analyses indicated subtype-dependent responses linked to TNFAIP dysregulation.
conclusionThis study provides a comprehensive multi-omics characterization of TNFAIP family genes in BC, addressing the role of inflammatory signaling in tumor progression and identifying potential biomarkers and therapeutic targets. These findings enhance the understanding of TNFAIP-mediated molecular networks and offer a resource for translational and experimental research in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.